(ASPI) ASP Isotopes Common Stock - Overview
Stock: Uranium-235, HALEU, Lithium-6, Molybdenum-100, Silicon-28
| Risk 5d forecast | |
|---|---|
| Volatility | 113% |
| Relative Tail Risk | -8.36% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.51 |
| Alpha | -30.23 |
| Character TTM | |
|---|---|
| Beta | 1.886 |
| Beta Downside | 0.982 |
| Drawdowns 3y | |
|---|---|
| Max DD | 83.33% |
| CAGR/Max DD | 0.55 |
Description: ASPI ASP Isotopes Common Stock December 25, 2025
ASP Isotopes Inc. (NASDAQ: ASPI) is a development-stage advanced materials firm that produces and markets isotopes through two business segments: Nuclear Fuels (focused on high-assay low-enriched uranium [HALEU] and Lithium-6) and Specialist Isotopes & Related Services (targeting niche isotopes such as C-14, Mo-100, Si-28 for pharma, agro-chemicals, medical imaging, and semiconductor applications). The company’s proprietary Aerodynamic Separation Process (ASP) and Quantum Enrichment (QE) technologies enable gas-phase isotope separation, and it currently commercializes molybdenum-100, molybdenum-98, and ytterbium-176 for nuclear medicine while developing additional isotopes for medical, energy, and semiconductor markets.
Key industry drivers that could affect ASP’s outlook include: (1) U.S. Department of Energy’s $2.2 billion HALEU funding program, which is expected to boost demand for advanced nuclear fuel supplies; (2) the global medical isotope market, projected to grow at a 6-8 % CAGR through 2030, driven by expanding PET imaging and targeted radiotherapy; and (3) semiconductor supply chain constraints that increase the premium on high-purity germanium isotopes for quantum-computing components. As of the latest filing, ASP’s cash runway is approximately 12 months, and its R&D spend represents roughly 30 % of total operating expenses-metrics that signal a high-risk, high-potential profile.
For a deeper, data-driven assessment of ASPI’s valuation and risk factors, you may find the analytical tools on ValueRay useful.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income: -105.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.15 > 0.02 and ΔFCF/TA 14.07 > 1.0 |
| NWC/Revenue: 1736 % < 20% (prev 1438 %; Δ 297.8% < -1%) |
| CFO/TA -0.10 > 3% & CFO -23.7m > Net Income -105.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 6.14 > 1.5 & < 3 |
| Outstanding Shares: last quarter (88.6m) vs 12m ago 43.91% < -2% |
| Gross Margin: 23.00% > 18% (prev 0.39%; Δ 2260 % > 0.5%) |
| Asset Turnover: 5.41% > 50% (prev 4.02%; Δ 1.39% > 0%) |
| Interest Coverage Ratio: -231.0 > 6 (EBITDA TTM -106.6m / Interest Expense TTM 400.0k) |
Altman Z'' -3.20
| A: 0.64 (Total Current Assets 173.9m - Total Current Liabilities 28.3m) / Total Assets 225.9m |
| B: -0.68 (Retained Earnings -152.6m / Total Assets 225.9m) |
| C: -0.60 (EBIT TTM -92.4m / Avg Total Assets 155.0m) |
| D: -1.17 (Book Value of Equity -150.7m / Total Liabilities 129.3m) |
| Altman-Z'' Score: -3.20 = D |
Beneish M 1.00
| DSRI: 36.10 (Receivables 50.1m/560.4k, Revenue 8.38m/3.38m) |
| GMI: 1.70 (GM 23.00% / 39.12%) |
| AQI: 2.03 (AQ_t 0.09 / AQ_t-1 0.04) |
| SGI: 2.48 (Revenue 8.38m / 3.38m) |
| TATA: -0.36 (NI -105.6m - CFO -23.7m) / TA 225.9m) |
| Beneish M-Score: 27.80 (Cap -4..+1) = D |
What is the price of ASPI shares?
Over the past week, the price has changed by -8.28%, over one month by -10.68%, over three months by -24.09% and over the past year by +0.95%.
Is ASPI a buy, sell or hold?
- StrongBuy: 1
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ASPI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 13 | 123.4% |
| Analysts Target Price | 13 | 123.4% |
| ValueRay Target Price | 7 | 21% |
ASPI Fundamental Data Overview February 04, 2026
P/S = 90.0641
P/B = 10.7005
Revenue TTM = 8.38m USD
EBIT TTM = -92.4m USD
EBITDA TTM = -106.6m USD
Long Term Debt = 99.5m USD (from longTermDebt, last quarter)
Short Term Debt = 13.0m USD (from shortTermDebt, last quarter)
Debt = 113.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -285.6k USD (from netDebt column, last quarter)
Enterprise Value = 754.8m USD (755.0m + Debt 113.7m - CCE 113.9m)
Interest Coverage Ratio = -231.0 (Ebit TTM -92.4m / Interest Expense TTM 400.0k)
EV/FCF = -22.22x (Enterprise Value 754.8m / FCF TTM -34.0m)
FCF Yield = -4.50% (FCF TTM -34.0m / Enterprise Value 754.8m)
FCF Margin = -405.1% (FCF TTM -34.0m / Revenue TTM 8.38m)
Net Margin = -1259 % (Net Income TTM -105.6m / Revenue TTM 8.38m)
Gross Margin = 23.00% ((Revenue TTM 8.38m - Cost of Revenue TTM 6.46m) / Revenue TTM)
Gross Margin QoQ = 8.65% (prev 47.74%)
Tobins Q-Ratio = 3.34 (Enterprise Value 754.8m / Total Assets 225.9m)
Interest Expense / Debt = 0.13% (Interest Expense 146.1k / Debt 113.7m)
Taxrate = 21.0% (US default 21%)
NOPAT = -73.0m (EBIT -92.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.14 (Total Current Assets 173.9m / Total Current Liabilities 28.3m)
Debt / Equity = 1.53 (Debt 113.7m / totalStockholderEquity, last quarter 74.1m)
Debt / EBITDA = 0.00 (negative EBITDA) (Net Debt -285.6k / EBITDA -106.6m)
Debt / FCF = 0.01 (negative FCF - burning cash) (Net Debt -285.6k / FCF TTM -34.0m)
Total Stockholder Equity = 47.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -68.10% (Net Income -105.6m / Total Assets 225.9m)
RoE = -222.6% (Net Income TTM -105.6m / Total Stockholder Equity 47.4m)
RoCE = -62.89% (EBIT -92.4m / Capital Employed (Equity 47.4m + L.T.Debt 99.5m))
RoIC = -61.61% (negative operating profit) (NOPAT -73.0m / Invested Capital 118.5m)
WACC = 11.19% (E(755.0m)/V(868.7m) * Re(12.86%) + D(113.7m)/V(868.7m) * Rd(0.13%) * (1-Tc(0.21)))
Discount Rate = 12.86% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 34.54%
Fair Price DCF = unknown (Cash Flow -34.0m)
EPS Correlation: -33.14 | EPS CAGR: 1.41% | SUE: 0.06 | # QB: 0
Revenue Correlation: 87.00 | Revenue CAGR: 324.8% | SUE: 1.48 | # QB: 1
EPS next Quarter (2026-03-31): EPS=-0.13 | Chg30d=+0.007 | Revisions Net=+1 | Analysts=3
EPS next Year (2026-12-31): EPS=-0.54 | Chg30d=+0.000 | Revisions Net=-1 | Growth EPS=+57.1% | Growth Revenue=+328.8%